Protagonist Therapeutics, Inc. (PTGX) Stock Overview
Explore Protagonist Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Protagonist Therapeutics, Inc. (PTGX)
Key Financials
Key Financials
Market Cap
9.1B
P/E Ratio
115.25
EPS (TTM)
$1.03
ROE
0.12%
PTGX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Protagonist Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of PTGX on the NASDAQ shows an RSI of 44.56, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $148.05 for the NASDAQ listing.
Key metrics behind Protagonist Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 115.25 and a market capitalization of 9.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of PTGX on the NASDAQ.